WO2017095898A1 - Utilisations de pyrimido-pyrimidazinones pour le traitement du cancer - Google Patents

Utilisations de pyrimido-pyrimidazinones pour le traitement du cancer Download PDF

Info

Publication number
WO2017095898A1
WO2017095898A1 PCT/US2016/064178 US2016064178W WO2017095898A1 WO 2017095898 A1 WO2017095898 A1 WO 2017095898A1 US 2016064178 W US2016064178 W US 2016064178W WO 2017095898 A1 WO2017095898 A1 WO 2017095898A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridazin
phenyl
oxo
amino
piperidin
Prior art date
Application number
PCT/US2016/064178
Other languages
English (en)
Inventor
Sanjeeva P. REDDY
Sandeep Gupta
Roger Astbury Smith
Original Assignee
Asana Biosciences, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2018124289A priority Critical patent/RU2018124289A/ru
Priority to CN201680081107.0A priority patent/CN108601785A/zh
Priority to AU2016365215A priority patent/AU2016365215A1/en
Priority to BR112018011196A priority patent/BR112018011196A2/pt
Priority to KR1020187017697A priority patent/KR20180084983A/ko
Priority to JP2018528583A priority patent/JP2018535995A/ja
Application filed by Asana Biosciences, Llc filed Critical Asana Biosciences, Llc
Priority to CA3006762A priority patent/CA3006762A1/fr
Priority to EP16813264.5A priority patent/EP3383399A1/fr
Priority to MX2018006776A priority patent/MX2018006776A/es
Publication of WO2017095898A1 publication Critical patent/WO2017095898A1/fr
Priority to ZA2018/03593A priority patent/ZA201803593B/en
Priority to IL259781A priority patent/IL259781A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

L'invention concerne des méthodes de traitement du cancer, qui comprennent l'administration au patient le nécessitant d'une quantité thérapeutiquement efficace d'un composé de Formule (I) ou d'un sel ou ester de qualité pharmaceutique de ce dernier. (Formule I) L'invention concerne également des méthodes d'inhibition de la croissance et de la prolifération de cellules cancéreuses in vitro ou in vivo, qui comprennent la mise en contact des cellules avec la quantité du composé de formule (I) qui est efficace pour inhiber la croissance ou la prolifération des cellules cancéreuses. L'invention concerne en outre des méthodes d'inhibition de la croissance tumorale, comprenant la mise en contact de la tumeur avec la quantité du composé de formule (I) qui est efficace pour inhiber la croissance de la tumeur.
PCT/US2016/064178 2015-12-04 2016-11-30 Utilisations de pyrimido-pyrimidazinones pour le traitement du cancer WO2017095898A1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CN201680081107.0A CN108601785A (zh) 2015-12-04 2016-11-30 嘧啶并哒嗪酮在治疗癌症中的用途
AU2016365215A AU2016365215A1 (en) 2015-12-04 2016-11-30 Uses of pyrimido-pyrimidazinones to treat cancer
BR112018011196A BR112018011196A2 (pt) 2015-12-04 2016-11-30 uso de pirimido-pirimidazinonas para tratar o câncer
KR1020187017697A KR20180084983A (ko) 2015-12-04 2016-11-30 암의 치료를 위한 피리미도-피리미다지논의 용도
JP2018528583A JP2018535995A (ja) 2015-12-04 2016-11-30 癌を治療するためのピリミド−ピリダジノンの使用
RU2018124289A RU2018124289A (ru) 2015-12-04 2016-11-30 Применения пиримидо-пиридазинонов для лечения рака
CA3006762A CA3006762A1 (fr) 2015-12-04 2016-11-30 Utilisations de pyrimido-pyridazinones pour le traitement du cancer
EP16813264.5A EP3383399A1 (fr) 2015-12-04 2016-11-30 Utilisations de pyrimido-pyrimidazinones pour le traitement du cancer
MX2018006776A MX2018006776A (es) 2015-12-04 2016-11-30 Usos de pirimido-piridazinonas para tratar el cancer.
ZA2018/03593A ZA201803593B (en) 2015-12-04 2018-05-30 Uses of pyrimido-pyrimidazinones to treat cancer
IL259781A IL259781A (en) 2015-12-04 2018-06-03 Uses of pyrimido-pyridazinones to treat cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562263398P 2015-12-04 2015-12-04
US62/263,398 2015-12-04

Publications (1)

Publication Number Publication Date
WO2017095898A1 true WO2017095898A1 (fr) 2017-06-08

Family

ID=57570591

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/064178 WO2017095898A1 (fr) 2015-12-04 2016-11-30 Utilisations de pyrimido-pyrimidazinones pour le traitement du cancer

Country Status (15)

Country Link
US (2) US10188654B2 (fr)
EP (1) EP3383399A1 (fr)
JP (1) JP2018535995A (fr)
KR (1) KR20180084983A (fr)
CN (1) CN108601785A (fr)
AR (1) AR106830A1 (fr)
AU (1) AU2016365215A1 (fr)
BR (1) BR112018011196A2 (fr)
CA (1) CA3006762A1 (fr)
IL (1) IL259781A (fr)
MX (1) MX2018006776A (fr)
RU (1) RU2018124289A (fr)
TW (1) TW201726141A (fr)
WO (1) WO2017095898A1 (fr)
ZA (1) ZA201803593B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2748166B1 (fr) * 2011-08-23 2018-07-11 Asana BioSciences, LLC Composés de pyrimido-pyridazinone et leurs procédés d'utilisation
CN111961035B (zh) * 2019-05-20 2022-11-01 南京科技职业学院 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009145856A1 (fr) * 2008-04-16 2009-12-03 Portola Pharmaceuticals, Inc. 2, 6-DIAMINO-PYRIMIDIN- B-YL-CARBOXAMIDES SERVANT D'INHIBITEURS DE Syk KINASES ET DE JANUS KINASES
WO2010019637A1 (fr) * 2008-08-12 2010-02-18 Smithkline Beecham Corporation Composés chimiques
WO2011053861A1 (fr) * 2009-10-29 2011-05-05 Genosco Inhibiteurs de kinases
US20130023523A1 (en) * 2011-07-19 2013-01-24 Abbott Laboratories Pyridazino[4,5-d]pyrimidin-5(6h)-one inhibitors of kinases
US20130053346A1 (en) * 2011-08-23 2013-02-28 Endo Pharmaceuticals Inc Pyrimido-pyridazinone compounds and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009145856A1 (fr) * 2008-04-16 2009-12-03 Portola Pharmaceuticals, Inc. 2, 6-DIAMINO-PYRIMIDIN- B-YL-CARBOXAMIDES SERVANT D'INHIBITEURS DE Syk KINASES ET DE JANUS KINASES
WO2010019637A1 (fr) * 2008-08-12 2010-02-18 Smithkline Beecham Corporation Composés chimiques
WO2011053861A1 (fr) * 2009-10-29 2011-05-05 Genosco Inhibiteurs de kinases
US20130023523A1 (en) * 2011-07-19 2013-01-24 Abbott Laboratories Pyridazino[4,5-d]pyrimidin-5(6h)-one inhibitors of kinases
US20130053346A1 (en) * 2011-08-23 2013-02-28 Endo Pharmaceuticals Inc Pyrimido-pyridazinone compounds and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RAO NIRANJAN S ET AL: "ASN002: A Potent Dual SYK/JAK Inhibitor Currently in a Phase I/II Study Shows Strong Antitumor Activity in Preclinical Studies", BLOOD, vol. 126, no. 23, 3 December 2015 (2015-12-03), & 57TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ORLANDO, FL, USA; DECEMBER 05 -08, 2015, XP009193517 *
REDDY SANJEEVA ET AL: "ASN002: A novel dual SYK/JAK inhibitor with strong antitumor activity", CANCER RESEARCH, vol. 75, no. Suppl. 15, August 2015 (2015-08-01), & 106TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH (AACR); PHILADELPHIA, PA, USA; APRIL 18 -22, 2015, pages 792, XP009193518 *

Also Published As

Publication number Publication date
RU2018124289A (ru) 2020-01-14
CN108601785A (zh) 2018-09-28
TW201726141A (zh) 2017-08-01
AR106830A1 (es) 2018-02-21
ZA201803593B (en) 2019-04-24
EP3383399A1 (fr) 2018-10-10
JP2018535995A (ja) 2018-12-06
AU2016365215A1 (en) 2018-07-05
IL259781A (en) 2018-07-31
KR20180084983A (ko) 2018-07-25
BR112018011196A2 (pt) 2018-11-21
US20190070182A1 (en) 2019-03-07
US20170157126A1 (en) 2017-06-08
CA3006762A1 (fr) 2017-06-08
MX2018006776A (es) 2018-08-15
US10188654B2 (en) 2019-01-29

Similar Documents

Publication Publication Date Title
ES2818620T3 (es) Derivados de azabencimidazol como inhibidores de pi3k beta
AU2010286569C1 (en) Compounds and compositions as protein kinase inhibitors
RU2632907C2 (ru) Дейтерированные диаминопиримидиновые соединения и фармацевтические композиции, содержащие такие соединения
DK2805940T3 (en) PYRAZINE CARBOXAMIDE COMPOUND
RU2687060C2 (ru) Фармацевтические соединения
JP5756518B2 (ja) 複素環アルキニルベンゼン化合物と、その医療用組成物および使用
AU2016311295A1 (en) Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
JP2010512338A5 (fr)
AU2016335086B2 (en) Quinoxaline and pyridopyrazine derivatives as pI3Kbeta inhibitors
JPWO2020045334A1 (ja) 光学活性なアザビシクロ環誘導体
WO2019189732A1 (fr) Dérivé d'amine secondaire cyclique réticulé optiquement actif
JP2022539208A (ja) チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
JP2012255038A (ja) 異常な細胞増殖の治療用のピリミジン誘導体
WO2017095898A1 (fr) Utilisations de pyrimido-pyrimidazinones pour le traitement du cancer
KR20220035031A (ko) 오로라 키나아제 억제제 및 이의 용도
KR102440296B1 (ko) 피라졸기로 치환된 피리미딘 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물
CA2891900C (fr) Derives d'indole utiles dans le traitement du cancer, des infections virales et des maladies pulmonaires
CN102482281A (zh) 吡咯并[2，3-d]嘧啶衍生物
US20220162204A1 (en) Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative
KR20230143959A (ko) 헤테로아릴 유도체 및 이의 용도
TW202400578A (zh) 新穎的化合物及其用於抑制檢查點激酶２的用途
AU2022232876A1 (en) Novel pyrimidine derivative showing inhibition effect on growth of cancer cells
EP4126847A1 (fr) Dérivés de quinazolinone et leurs utilisations pour le traitement d'un cancer
KR20240046408A (ko) 단백질 키나아제 저해 활성을 갖는 피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물
EP4342895A1 (fr) Composé dérivé d'hétéroaryle et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16813264

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3006762

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2018528583

Country of ref document: JP

Ref document number: MX/A/2018/006776

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 259781

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018011196

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20187017697

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201807454

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 2016365215

Country of ref document: AU

Date of ref document: 20161130

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112018011196

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180601